The Week in Review: New Deals in China Life Science

Merck, Lilly and Pfizer will work together to compile a pharmacogenomic gastric and lung cancer database in Singapore; the PRC authorized 37 billion RMB ($5.5 billion) to increase access to medical care; WuXi PharmaTech (药明康德) is expanding services to keep revenues growing; WuXi also received AAALAC Accreditation for its new Suzhou tox lab; China Cord Blood Corp. paid $20.5 million for a 20% equity interest in Shandong Cord Blood Bank; Fosun Pharma will invest $9.7 million into Biosino Bio-Technology; Beijing Shenghong Biotech paid $4.1 million for four new drug projects; Lundbeck authorized Teva Pharma to distribute its Parkinson’s treatment in China; China Aoxing will collaborate with QRxPharma Limited to develop its narcotic combination in China; and Indian CMO Dishman hopes to have its Shanghai facility operational by September 2010. More details… Stock Symbols: (NYSE: MRK) (NYSE: LLY) (NYSE: PFE) (NYSE: WX) (NYSE: CO) (CPH: LUN) (NSDQ: TEVA) (OTCBB: CAXG) (ASX: QRX and OTCQX: QRXPY)